ProNAi Therapeutics (DNAI) Sees IPO Price of $14 - $16/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
ProNAi Therapeutics (DNAI) Sees IPO Pricing of ~$17/Share, Above Previous Range
July 15, 2015 2:22 PM EDTProNAi Therapeutics, Inc. (Nasdaq: DNAI) filed a amended registration with the U.S. SEC for an IPO of its Common Stock. The company plans to sell 8.1 million shares and sees an offering price of about $17 per share. Previously, the company was planning to offer 6.7 million shares with an expected offering price of $14 to $16 per share. The company will trade on the Nasdaq Global Market under the ticker, "DNAI."
Underwriters are Jefferies, BofA Merrill Lynch, Wedbush PacGrow, and SunTrust Robinson Humphrey.
ProNAi Therapeutics... More
